The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a genetically inherited risk ...

Did you know men and women's heart cells prefer different kinds of fuel? Gender differences are emerging as scientists turn ...

Discover how the experimental drug lepodisiran dramatically lowers lipoprotein(a) levels, potentially transforming treatment ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

While heart disease cannot be cured or reversed, some of the risk factors can be managed through healthy lifestyle choices.

Patients with MASLD had nearly twice the all-cause mortality rate as the general population, suggesting the need for ...

Several studies have reported that the coronavirus disease 2019 (COVID-19) can lead to heart rate variability (HRV), with the ...

The Economic Survey 2024-25 reveals an expected increase in Goa's population to 15.96 lakh by 2025 but highlights worrying ...

The Eli Lilly drug caused a major drop in the blood levels of Lp(a), but further research is needed to show that it will ...

Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 14% in patients with type 2 ...

Wegovy was also associated with a lower risk of hospitalization for heart failure, cardiovascular-related death, and ...

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...